Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + liposomal mitoxantrone hydrochloride
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Tislelizumab + liposomal mitoxantrone hydrochloride is a combination therapy being investigated for relapsed/refractory extranodal NK/T cell lymphoma (ENKTL). Tislelizumab is a humanized immunoglobulin G4 variant monoclonal antibody against PD-1, while liposomal mitoxantrone hydrochloride (PLM60/Lipo-MIT) is a nano-drug formulation of mitoxantrone that enhances drug stability, sustains release, and targets tumor tissues more effectively. The liposomal formulation alters the pharmacokinetics and tissue distribution of mitoxantrone, resulting in improved anti-tumor efficacy and potentially reduced toxicity. This combination is currently being evaluated in clinical trials for its safety and efficacy in treating ENKTL, which is a highly aggressive malignancy associated with Epstein-Barr virus infection.
- Brand names
- Duoen
- Other names
- Mitoxantrone hydrochloride liposome with tislelizumab
02
Targets
TOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + liposomal mitoxantrone hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + liposomal mitoxantrone hydrochloride.